$7.44
0.40%
Nasdaq, Dec 26, 10:00 pm CET
ISIN
US48576U1060
Symbol
KPTI

Karyopharm Therapeutics, Inc. Stock price

$7.44
+1.89 34.05% 1M
+2.95 65.70% 6M
-2.70 26.66% YTD
-1.56 17.33% 1Y
-31.41 80.85% 3Y
-223.86 96.78% 5Y
-198.06 96.38% 10Y
-233.31 96.91% 20Y
Nasdaq, Closing price Fri, Dec 26 2025
-0.03 0.40%
ISIN
US48576U1060
Symbol
KPTI
Industry

Key metrics

Basic
Market capitalization
$126.9m
Enterprise Value
$344.0m
Net debt
$217.1m
Cash
$45.9m
Shares outstanding
8.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.9 | 0.8
EV/Sales
2.4 | 2.3
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-113.1%
Return on Equity
41.1%
ROCE
-1,148.2%
ROIC
-241.1%
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
$142.5m | $150.8m
EBITDA
$-103.8m | $-132.6m
EBIT
$-104.1m | $-98.0m
Net Income
$-124.6m | $-109.4m
Free Cash Flow
$-89.3m
Growth (TTM | estimate)
Revenue
-4.0% | 3.8%
EBITDA
17.4% | -11.3%
EBIT
17.3% | 18.0%
Net Income
-42.5% | -43.1%
Free Cash Flow
25.9%
Margin (TTM | estimate)
Gross
95.9%
EBITDA
-72.8% | -87.9%
EBIT
-73.1%
Net
-87.4% | -72.5%
Free Cash Flow
-62.7%
More
EPS
$-14.4
FCF per Share
$-10.3
Short interest
1.8%
Employees
279
Rev per Employee
$520.0k
Show more

Is Karyopharm Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Karyopharm Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:

Buy
83%
Hold
17%

Financial data from Karyopharm Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
143 143
4% 4%
100%
- Direct Costs 5.80 5.80
6% 6%
4%
137 137
4% 4%
96%
- Selling and Administrative Expenses 110 110
8% 8%
77%
- Research and Development Expense 131 131
12% 12%
92%
-104 -104
17% 17%
-73%
- Depreciation and Amortization 0.36 0.36
6% 6%
0%
EBIT (Operating Income) EBIT -104 -104
17% 17%
-73%
Net Profit -125 -125
42% 42%
-87%

In millions USD.

Don't miss a Thing! We will send you all news about Karyopharm Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Karyopharm Therapeutics, Inc. Stock News

Neutral
PRNewsWire
20 days ago
NEWTON, Mass. , Dec. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m.
Neutral
PRNewsWire
27 days ago
NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock and an  aggregate of 15,791 restricted stock units (RSUs) to seven newly-hired employees.
Neutral
PRNewsWire
27 days ago
NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 37th Annual Healthcare Conference in a fireside chat on Thursday, December 4, 2025 at 10:30 a.m.
More Karyopharm Therapeutics, Inc. News

Company Profile

Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Head office United States
CEO Richard Paulson
Employees 279
Founded 2008
Website karyopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today